Loading...
•
Dec 31, 2020
Mesa Labs Q3 2021 Earnings Report
Mesa Labs reported an increase in revenues and operating income, but a decrease in net income.
Key Takeaways
Mesa Labs reported an 8% increase in revenues and a significant increase in operating income for the third quarter of FY21. However, net income decreased slightly compared to the same quarter in the prior year. The company highlighted strong performance in its Sterilization and Disinfection Control division and the impact of currency exchange rates on the Biopharmaceutical Development division.
Revenues increased by 8% compared to the prior year.
Operating income increased significantly, by 101% compared to the prior year.
Net loss decreased by 1% compared to the same quarter in the prior year.
Sterilization and Disinfection Control division showed strong revenue growth of 13%.
Mesa Labs
Mesa Labs
Mesa Labs Revenue by Segment
Revenue by Segment
Sterilization & Disinfection Control Revenue
CapyFin.comBiopharmaceutical Development Revenue
CapyFin.com Forward Guidance
Mesa Labs anticipates a positive impact from mass vaccination efforts and expects continued economic recovery, while remaining prepared for potential stalls or delays. With strong cash flow and over $250 million in cash, the company is positioned for further organic and inorganic growth investments.
Positive Outlook
- Positive impact of mass vaccination in the coming quarters on both the health of humanity and our business.
- Positively biased toward continued economic recovery.
- Strong positive cash flow.
- Over $250 million in cash on the balance sheet.
- Well positioned to invest for further growth both inorganically and organically.
Challenges Ahead
- Ongoing COVID-19 headwinds.
- Potential stall or delay in economic recovery.
- Impact of COVID-19 on the ability to service customers and complete system installations.
- Strengthening of the SEK to the U.S. Dollar increased both cost of revenues and operating expenses incurred primarily in Sweden.
- Full biopharma lab reopenings stalled during the quarter with an estimated 40% of global labs still operating at reduced capacity.
Revenue & Expenses
Visualization of income flow from segment revenue to net income